Prosecution Insights
Prosecution Insights
Tech Center 2800 • Art Units: 1600 1614 1624 1626 1629 1644 2897
This examiner grants 75% of resolved cases
Brenda Libby Coleman is an examiner in Tech Center 2800 and Art Unit 1600. She has a caseload of 1643 resolved cases and an allowance rate of 74.9 percent. This rate suggests the environment for applicants. The median days to allowance is 883, indicating the prosecution process timeline.
The interview lift is 15.5 percent. This lift shows that interviews are an effective way to further increase the 74.9 percent allowance rate. In Tech Center 2800, the 883 days median to allowance reflects the timeline for reaching a resolution.
With 1643 resolved cases, the examiner's statistics are reliable. The 74.9 percent allowance rate and the 883 days median to allowance are indicators for applicants in Art Unit 1600. The 15.5 percent interview lift remains an option for resolving outstanding issues. The combination of these metrics defines the current prosecution landscape for this examiner.
| App # | Title | Status | Assignee |
|---|---|---|---|
| 17768508 | MATERIALS FOR ORGANIC ELECTROLUMINESCENT DEVICES | Non-Final OA | Merck Patent GmbH |
| 18741024 | SOLVATE AND METHOD OF MANUFACTURING SOLVATE | Non-Final OA | FUJIFILM Corporation |
| 18252217 | 3-AMINO PYRROLIDINE AND PIPERIDINE MACROCYCLIC OREXIN RECEPTOR AGONISTS | Non-Final OA | Merck Sharp & Dohme LLC |
| 18856782 | NOVEL SUBSTITUTED 4-AMINO-4-OXO-BUT-2-ENYL DERIVATIVES, PROCESSES FOR THEIR PREPARATION AND THERAPEUTIC USES THEREOF | Non-Final OA | SANOFI |
| 18423776 | TRIAZOLOPYRIMIDINE COMPOUNDS AND USES THEREOF | Non-Final OA | NOVARTIS AG |
| 17625059 | TREATMENT OF PULMONARY FIBROSIS USING INHIBITORS OF NEU1 SIALIDASE | Non-Final OA | The United States Government as represented by the Department of Veterans Affairs |
| 18264109 | COMPOUNDS, COMPOSITIONS, AND METHODS OF USING THE SAME | Non-Final OA | The Board of Trustees of the University of Illinois |
| 18851760 | COMPOUNDS USABLE AS MODULATORS OF PERK ACTIVITY | Non-Final OA | Ramot at Tel-Aviv University Ltd. |
| 18422786 | HALOACETHYDRAZIDES USEFUL AS AEP INHIBITORS | Final Rejection | Hoffmann-La Roche Inc. |
| 17298599 | AMPA RECEPTOR ANTAGONISTS SPECIFIC FOR CALCIUM PERMEABLE AMPA RECEPTORS AND METHODS OF TREATMENT THEREWITH | Non-Final OA | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA |
| 18273678 | COMPOSITIONS AND METHODS FOR THE IDENTIFICATION OF COMPOUNDS THAT PROTECT AGAINST LIPOFUSCIN CYTOTOXICITY | Final Rejection | Cornell University |
| 18839283 | PROCESSES FOR THE PREPARATION OF N-(1-METHYLCYCLOPROPYL)-2-(3-PYRIDINYL)-2H-INDAZOLE-4-CARBOXAMIDE AND INTERMEDIATES THEREOF | Non-Final OA | FMC CORPORATION |
| 18851859 | SYNTHESIS OF DOPAMINE D3 RECEPTOR SELECTIVE ANTAGONISTS/PARTIAL AGONISTS | Non-Final OA | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH & HUMAN SERVICES |
| 18778225 | Crystal Modifications of Odevixibat | Non-Final OA | Albireo AB |
| 18849031 | CRYSTAL OF FUSED TRICYCLIC DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | Non-Final OA | CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD. |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy